Regeneron offers a positive look at the first cut of its Covid-19 antibody cocktail — but just how well does it protect a vulnerable group?
On the heels of a disappointing performance by Eli Lilly’s antibody targeting the coronavirus, Regeneron is now stepping up with evidence that its antibody …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
